KRAS G12V mutation is an adverse prognostic factor of Chinese gastric cancer patients

25Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

Abstract

This study aims to investigate the molecular characteristics of Chinese gastric cancer patients. In our study, the KRAS, BRAF, and PIK3CA mutation status of 485 GC patients were analyzed by Sanger sequencing. Kaplan-Meier analysis was used to plot survival curves according to different genotypes. The results show that the frequency of KRAS, BRAF and PIK3CA mutations were 4.1%, 1.2% and 3.5%, respectively. BRAF mutations were significantly concentrated in stage III and IV gastric cancer (P=0.009). KRAS G12V mutation carriers have much shorter OS than other mutation carriers and wild-type group patients (P=0.013). In conclusion, only the KRAS G12V mutation has an adverse effect on patient survival.

Author supplied keywords

Cite

CITATION STYLE

APA

Fu, X. H., Chen, Z. T., Wang, W. H., Fan, X. J., Huang, Y., Wu, X. B., … Wang, J. P. (2019). KRAS G12V mutation is an adverse prognostic factor of Chinese gastric cancer patients. Journal of Cancer, 10(4), 821–828. https://doi.org/10.7150/jca.27899

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free